[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2170069T3 - 1-alfa-hidroxiprevitamina d para administracion oral. - Google Patents

1-alfa-hidroxiprevitamina d para administracion oral.

Info

Publication number
ES2170069T3
ES2170069T3 ES93916684T ES93916684T ES2170069T3 ES 2170069 T3 ES2170069 T3 ES 2170069T3 ES 93916684 T ES93916684 T ES 93916684T ES 93916684 T ES93916684 T ES 93916684T ES 2170069 T3 ES2170069 T3 ES 2170069T3
Authority
ES
Spain
Prior art keywords
vitamin
hydroxiprevitamine
alfa
oral administration
hydroxyprevitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93916684T
Other languages
English (en)
Inventor
Joyce C Knutson
Charles R Valliere
Charles W Bishop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bone Care International Inc
Original Assignee
Bone Care International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bone Care International Inc filed Critical Bone Care International Inc
Application granted granted Critical
Publication of ES2170069T3 publication Critical patent/ES2170069T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

METODO DE INCREMENTAR EL NIVEL EN SANGRE DE VITAMINA D ACTIVADA POR ADMINISTRACION ORAL DE 1ALFA-HIDROXIPROVITAMINA D O UNA FORMULACION EN VERSION MANTENIDA Y RETARDADA DE VITAMINA D ACTIVADA O UNA COMBINACION DE ELLAS. AMBAS LA FORMA DE PROVITAMINA D Y LA FORMULACION DE VITAMINA D ACTIVADA EN VERSION MANTENIDA Y RETARDADA INCREMENTAN EL NIVEL EN SANGRE DE VITAMINA D SIN RIESGO IMPORTANTE DE HIPERCALCEMIA ASOCIADA CON OTRAS FORMAS DE DOSIFICACION DE VITAMINA D.
ES93916684T 1992-06-22 1993-06-22 1-alfa-hidroxiprevitamina d para administracion oral. Expired - Lifetime ES2170069T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90188692A 1992-06-22 1992-06-22

Publications (1)

Publication Number Publication Date
ES2170069T3 true ES2170069T3 (es) 2002-08-01

Family

ID=25414989

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93916684T Expired - Lifetime ES2170069T3 (es) 1992-06-22 1993-06-22 1-alfa-hidroxiprevitamina d para administracion oral.

Country Status (11)

Country Link
US (6) US5622941A (es)
EP (1) EP0600079B1 (es)
JP (1) JP3722832B2 (es)
AT (1) ATE211387T1 (es)
AU (2) AU4645893A (es)
CA (1) CA2116238C (es)
DE (1) DE69331409T2 (es)
DK (1) DK0600079T3 (es)
ES (1) ES2170069T3 (es)
NZ (1) NZ254424A (es)
WO (1) WO1994000128A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US5493027A (en) * 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US5696103A (en) * 1995-11-17 1997-12-09 Syntex (U.S.A.) Inc. Method for treating osteoporosis
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6929797B2 (en) * 1997-02-13 2005-08-16 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
AU762481C (en) 1998-03-27 2004-08-19 Oregon Health Sciences University Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
DE19916419B4 (de) * 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
US6051567A (en) * 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
IL153378A0 (en) * 2000-07-18 2003-07-06 Bone Care Internat Inc STABILIZED 1alpha-HYDROXY VITAMIN D
US7858602B2 (en) 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
KR20050044655A (ko) * 2001-12-03 2005-05-12 노바세아, 인크. 활성 비타민 ｄ 화합물을 함유하는 약제학적 조성물
US20050026871A1 (en) * 2002-07-17 2005-02-03 Moshe Flashner-Barak Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
US7566696B2 (en) * 2002-09-05 2009-07-28 Wisconsin Alumni Research Foundation Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20040162292A1 (en) * 2002-12-03 2004-08-19 Evenstad Kenneth L. Multivitamin formulations for promoting healthy collagen, and methods of their use
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20050148557A1 (en) * 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
AU2004296877A1 (en) * 2003-12-09 2005-06-23 Incyte Corporation Dosing methods for ss-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
WO2006088765A1 (en) * 2005-02-14 2006-08-24 Wisconsin Alumni Research Foundation Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
CA2624897C (en) * 2005-10-12 2017-02-14 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
HUE029572T2 (en) * 2006-02-03 2017-03-28 Opko Renal Llc Treatment of Vitamin D Insufficiency and Deficiency with 25-Hydroxy-D2 and 25-Hydroxy-D3
ES2791535T3 (es) 2006-06-21 2020-11-04 Opko Ireland Global Holdings Ltd Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
JP5647516B2 (ja) 2007-04-25 2014-12-24 シトクロマ インコーポレイテッド ビタミンｄ療法のための方法および化合物
EP2148683A4 (en) 2007-04-25 2012-09-12 Proventiv Therapeutics Llc METHOD FOR THE SAFE AND EFFECTIVE TREATMENT AND PREVENTION OF SECONDARY HYPERPARATHYREOSIS IN CHRONIC KIDNEY DISEASE
CN101668532B (zh) 2007-04-25 2014-08-20 赛特克罗公司 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的组合物及其相应的制药用途
PL2148661T3 (pl) * 2007-04-25 2013-07-31 Cytochroma Inc Doustne kompozycje o kontrolowanym uwalnianiu zawierające związek będący witaminą D i woskowy nośnik
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
CA2797537C (en) 2010-03-29 2021-11-23 Cytochroma Inc. Use of 25-hydroxyvitamin d compound for reducing parathyroid levels
US9416102B2 (en) * 2013-01-23 2016-08-16 Wisconsin Alumni Research Foundation (22E)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 analogs
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
SG11201808227YA (en) 2016-03-28 2018-10-30 Opko Ireland Global Holdings Limited Methods of vitamin d treatment
SG11202101905YA (en) * 2018-08-31 2021-03-30 Opko Ireland Global Holdings Ltd Vitamin d pediatric dosage forms, methods of making and using

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2216719A (en) * 1935-07-06 1940-10-08 Hartford Nat Bank & Trust Co Vitamin
US2434015A (en) * 1942-11-21 1948-01-06 Du Pont Stable provitamin d composition
US4335120A (en) * 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4230701A (en) * 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
ATE19623T1 (de) * 1981-07-17 1986-05-15 Duphar Int Res Verfahren zur herstellung von 1-alpha-hydroxy vitamin d oder 1-alpha hydroxy previtamin d derivaten und previtamin d oder tachysteroladdukten mit geeigneten dienophilen.
JPS5910562A (ja) * 1982-07-07 1984-01-20 Teijin Ltd プレ−１α−ヒドロキシコレカルシフエロ−ル類の製造法
DE3448412C2 (es) * 1983-05-09 1991-12-12 Wisconsin Alumni Res Found
US4505906A (en) * 1984-01-30 1985-03-19 Wisconsin Alumni Research Foundation Hydroxyvitamin D2 isomers
US4684524A (en) * 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4728643A (en) * 1984-11-02 1988-03-01 The General Hospital Corporation Method of treating psoriasis
GB2183156B (en) * 1985-03-14 1989-06-21 Chugai Pharmaceutical Co Ltd Composition for treating skin disease
JPS649932A (en) * 1987-07-01 1989-01-13 Toyo Capsel Kk Soft capsule preparation using newly combined component as the base
ZA886284B (en) * 1987-08-31 1990-04-25 Advanced Polymer Systems Inc Controlled release formulations
AU5185790A (en) * 1989-02-16 1990-09-05 University Of Georgia Research Foundation, Inc., The Treatment of tibial dyschondroplasia
US5013728A (en) * 1990-05-04 1991-05-07 Colgate - Palmolive Company Composition for treating osteoporosis and hormonal imbalance
ES2169023T3 (es) * 1990-09-21 2002-07-01 Bone Care Int Inc Nueva 1alfa-hidroxi vitaminada d4 y nuevos intermedios y analogos.
JPH04198129A (ja) * 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンｄ↓３類含有組成物

Also Published As

Publication number Publication date
JP3722832B2 (ja) 2005-11-30
ATE211387T1 (de) 2002-01-15
US5529991A (en) 1996-06-25
EP0600079A1 (en) 1994-06-08
DE69331409D1 (de) 2002-02-07
NZ254424A (en) 1997-09-22
EP0600079B1 (en) 2002-01-02
US6150346A (en) 2000-11-21
JPH07501343A (ja) 1995-02-09
AU4645893A (en) 1994-01-24
CA2116238C (en) 2007-09-04
AU6060896A (en) 1996-10-03
US6147064A (en) 2000-11-14
AU696402B2 (en) 1998-09-10
CA2116238A1 (en) 1994-01-06
US5614513A (en) 1997-03-25
US6133250A (en) 2000-10-17
DK0600079T3 (da) 2002-04-15
WO1994000128A1 (en) 1994-01-06
US5622941A (en) 1997-04-22
DE69331409T2 (de) 2002-08-29

Similar Documents

Publication Publication Date Title
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
ATE306266T1 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
NO306457B1 (no) 2,4-disulfonylfenylbutylnitron, salter derav, farmasöytisk sammensetning, samt anvendelse av denne forbindelse til fremstilling av et medikament
IT1270594B (it) Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
GR3004509T3 (es)
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
NO920740L (no) Doseringsform for oral administrering av hypoglykemisk glipizid
NO306377B1 (no) Doseform for avgivelse av et medikament
GR1000465B (el) Μεθοδος παρασκευης φαρμακευτικων συνθεσεων που περιεχουν ακετυλ d-καρνιτινη για την θεραπευτικη αγωγη του γλαυκωματος.
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
KR970025615A (ko) 암 전이 억제제
ES2147788T3 (es) 3,4-diarilcromanos para el tratamiento de la dermatitis.
GR1000419B (el) Μορφη δοσολογιας για χορηγηση ανταγωνιστη του ασβεστιου.
IT1244636B (it) Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
MY100780A (en) Azumolene dosage form.
AR002946A1 (es) Un conjunto para uso en el tratamiento o la prevencion de la osteoporosis en los mamiferos de acuerdo con una dieta ciclica.
SE8304818D0 (sv) A medicine having anti-ulcer, spasmolytic and locally anesthetic effect
ITMI931104A1 (it) Preparazione di una forma farmaceutica atta a combattere l'iperinsulinismo
AR003957A1 (es) Composicion farmaceutica para tratar un paciente mamifero que sufre una enfermedad vascular cronica progresiva (cpvd)
CO4180553A1 (es) Composiciones para el tratamiento de la peridontitis adulta

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 600079

Country of ref document: ES